| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
26,456 |
20,011 |
$1.82M |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
1,814 |
1,646 |
$95K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
1,724 |
1,594 |
$91K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
1,349 |
1,227 |
$69K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
1,337 |
1,166 |
$49K |
| 99215 |
Prolong outpt/office vis |
445 |
347 |
$47K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,568 |
1,362 |
$32K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
496 |
466 |
$26K |
| 90686 |
|
2,030 |
1,883 |
$24K |
| 99205 |
Prolong outpt/office vis |
138 |
112 |
$15K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
694 |
625 |
$8K |
| 90674 |
|
312 |
302 |
$4K |
| 90670 |
|
360 |
336 |
$4K |
| 90734 |
|
305 |
281 |
$3K |
| 69210 |
|
93 |
88 |
$3K |
| 90651 |
|
317 |
299 |
$3K |
| 90688 |
|
147 |
146 |
$1K |
| 90648 |
|
121 |
112 |
$1K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
39 |
28 |
$1K |
| 90656 |
|
67 |
61 |
$880.65 |
| 90657 |
|
58 |
56 |
$880.65 |
| 90680 |
|
91 |
83 |
$824.48 |
| 99188 |
|
37 |
35 |
$598.50 |
| 87807 |
|
46 |
44 |
$598.46 |
| 90723 |
|
59 |
55 |
$562.78 |
| 90685 |
|
53 |
51 |
$478.00 |
| T1502 |
Administration of oral, intramuscular and/or subcutaneous medication by health care agency/professional, per visit |
80 |
74 |
$121.60 |
| 90633 |
|
15 |
13 |
$105.16 |
| 90715 |
|
13 |
13 |
$105.16 |